Traxam — Competitive Intelligence Brief

Traxam (FELBINAC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: felbinac. Area: Immunology.

phase 3 felbinac Prostaglandin G/H synthase 1 Immunology Small molecule

Target snapshot

Traxam (FELBINAC). Traxam works by blocking the production of prostaglandins, hormone-like substances that cause pain and inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Traxam TARGET	FELBINAC		phase 3	felbinac	Prostaglandin G/H synthase 1
Joicela	LUMIRACOXIB	Novartis Pharmaceuticals UK Limited	marketed	lumiracoxib	Prostaglandin G/H synthase 1	2005-01-01
Etocox	ETORICOXIB		marketed	etoricoxib	Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1	2002-01-01
Colazal	BALSALAZIDE	Valeant Pharms Intl	marketed	Aminosalicylate	Prostaglandin G/H synthase 1	2000-01-01
MOFEZOLAC	MOFEZOLAC		marketed	mofezolac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1	1994-01-01
(+)-Ketoprofen	DEXKETOPROFEN		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1994-01-01
DEXIBUPROFEN	DEXIBUPROFEN		marketed	dexibuprofen	Prostaglandin G/H synthase 1	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (felbinac class)

1. · 1 drug in this class